VYNE Therapeutics Inc.
VYNE
$1.43
-$0.45-23.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -39.83M | -34.00M | -28.43M | -29.08M | -28.45M |
| Total Depreciation and Amortization | 4.00K | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 859.00K | 1.16M | 1.80M | 2.40M | 3.05M |
| Change in Net Operating Assets | 5.00M | 2.73M | -120.00K | -1.17M | 60.00K |
| Cash from Operations | -33.97M | -30.11M | -26.75M | -27.85M | -25.34M |
| Capital Expenditure | -117.00K | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.48M | -51.73M | -46.90M | -65.92M | -57.35M |
| Cash from Investing | 23.37M | -51.73M | -46.90M | -65.92M | -57.35M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 82.67M | 82.67M | 82.67M | 82.82M |
| Repurchase of Common Stock | -141.00K | -11.00K | -56.00K | -58.00K | -67.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | 0.00 | 0.00 | 0.00 | -360.00K |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -141.00K | 82.65M | 82.61M | 82.61M | 82.39M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.75M | 817.00K | 8.95M | -11.16M | -301.00K |